Daré Bioscience Participates in Virtual Investor “What This Means” Segment
Rhea-AI Summary
Daré Bioscience (NASDAQ: DARE) announced CEO Sabrina Martucci Johnson’s participation in a Virtual Investor segment highlighting the FDA clearance of the IND for DARE-HPV on March 12, 2026 and plans to advance the program into a Phase 2 clinical study.
The CEO outlined how DARE-HPV would differ from current management of persistent high-risk HPV, noted the absence of any FDA-approved drug therapy for that condition, described anticipated timelines, potential risks, upcoming catalysts, and cited non-dilutive ARPA-H funding supporting the program.
Positive
- FDA IND clearance for DARE-HPV on March 12, 2026
- Phase 2 clinical advancement planned for DARE-HPV
- Non-dilutive funding secured via ARPA-H contract
Negative
- No FDA-approved drug therapy exists for persistent high-risk HPV
- Phase 2 clinical and regulatory outcomes remain uncertain
News Market Reaction – DARE
On the day this news was published, DARE declined 1.33%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
DARE is modestly higher (+0.67%) while several high-affinity biotech peers like TENX (-0.81%), ALLR (-1.22%), KZR (-0.43%), and CVKD (-1.14%) are down, with only NRSN (+3.00%) higher. Momentum scans show one peer (ANTX) moving down, suggesting stock-specific rather than sector-driven dynamics.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 23 | IND clearance | Positive | +0.6% | FDA cleared IND enabling Phase 2 study of DARE-HPV with ARPA-H support. |
| Feb 11 | Commercial rollout | Positive | +1.8% | Nationwide telehealth access launched for DARE to PLAY Sildenafil Cream. |
| Dec 10 | Product pre-orders | Positive | +7.0% | Pre-orders opened for DARE to PLAY Sildenafil Cream in select states. |
| Dec 01 | Rights returned | Neutral | -9.2% | Bayer returned Ovaprene rights; Daré retains Phase 3 program and funding. |
| Nov 24 | Grant funding | Positive | +6.5% | Received additional Gates Foundation grant tranche to support contraceptive R&D. |
Recent positive operational milestones (IND clearance, product launches, grant funding) have generally aligned with same-day or next-day share gains, while the Ovaprene rights transition and ongoing Phase 3 program coincided with a notable decline, highlighting mixed reactions when strategic complexity is high.
Over the last six months, Daré has advanced multiple women’s health programs. FDA IND clearance for DARE-HPV on Feb 23, 2026 and today’s investor segment underline a growing focus on high‑risk HPV. Commercial steps for DARE to PLAY™ Sildenafil Cream, including pre‑orders on Dec 10, 2025 and telehealth expansion on Feb 11, 2026, show execution on its sexual health strategy. Ovaprene’s Phase 3 program, Bayer’s rights return, and added Gates Foundation funding frame a pipeline supported by non‑dilutive capital but also strategic transition.
Market Pulse Summary
This announcement underscores Daré’s effort to educate investors on the FDA-cleared IND and planned Phase 2 study for DARE-HPV, targeting persistent high‑risk HPV infection with no approved drug therapy. It builds on the earlier IND clearance and ARPA-H–supported program. Investors may track progress toward trial initiation, clarity on timelines and risks, and how this asset complements Ovaprene’s ongoing Phase 3 program and the commercial rollout of DARE to PLAY™.
Key Terms
investigational new drug regulatory
phase 2 medical
human papillomavirus medical
hpv medical
non-dilutive funding financial
advanced research projects agency for health regulatory
arpa-h regulatory
AI-generated analysis. Not financial advice.
Sabrina Martucci Johnson, President and CEO of Daré Bioscience, discusses FDA clearance of the IND for DARE-HPV, the planned Phase 2 clinical study, and what the program could mean for women’s health
Access the segment here
SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced that Sabrina Martucci Johnson, President and Chief Executive Officer of Daré Bioscience, participated in a Virtual Investor “What This Means” segment highlighting the recent U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for the Company’s planned Phase 2 clinical study of DARE-HPV. Access the segment here.
As part of the segment, Ms. Johnson discusses the significance of the FDA’s IND clearance and how this milestone allows Daré to advance DARE-HPV into Phase 2 clinical development in alignment with Daré’s broader strategy to address unmet needs in women’s health. She explains how DARE-HPV treatment would differ from current clinical management of persistent high-risk human papillomavirus (HPV) infection, a condition with no FDA-approved drug therapy, and outlines key considerations for investors as Daré prepares for the Phase 2 trial of DARE-HPV, including anticipated timelines for study initiation, potential risks, and upcoming catalysts. Ms. Johnson also highlights the Company’s non-dilutive funding support, including its contract for funding from the Advanced Research Projects Agency for Health (ARPA-H), and discusses how positive Phase 2 data could position Daré Bioscience within the women’s health biotechnology landscape from both a scientific and market opportunity perspective.
The Virtual Investor “What This Means” segment featuring Daré Bioscience is now available here.
About Daré Bioscience
Daré Bioscience is a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions. Every innovation Daré advances is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, pelvic pain to fertility, vaginal health to infectious disease, Daré is working to close critical gaps in care using science that serves her needs.
For decades, women have been told to “wait it out” or “live with it,” while innovations that could improve their quality of life languish in the regulatory or funding pipeline. With growing awareness around menopause, sexual health, and vaginal health, the conversation is shifting. However, access to real, evidence-based solutions continues to lag. Daré was founded to change that. As a female-led health biotech company, Daré is accelerating the development of credible, science-based solutions that meet the high standards of clinical rigor – randomized, controlled trials; validated endpoints; peer-reviewed publications; and current Good Manufacturing Practice (cGMP) requirements.
To learn more about Daré’s mission to deliver differentiated therapies for women and its innovation pipeline, please visit www.darebioscience.com.
Daré Bioscience leadership has been named on the Medicine Maker’s Power List and Endpoints News’ Women in Biopharma and Daré's CEO has been honored as one of Fierce Pharma’s Most Influential People in Biopharma for Daré’s contributions to innovation and advocacy in the women’s health space.
Daré may announce material information about its finances, products and product candidates, clinical trials and other matters using the Investors section of its website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company and may also use social media to communicate important information about the company, its finances, products and product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts in the Investors section of its website and to follow these X (formerly Twitter) accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted in the Investors section of Daré’s website.
Forward-Looking Statements
Daré cautions you that all statements, other than statements of historical facts, contained in this press release and the “What This Means” segment featuring Ms. Johnson, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “prepare,” “seek,” “should,” “would,” “target,” “objective,” “positioned,” or the negative version of these words and similar expressions. In this press release and the “What This Means” segment featuring Ms. Johnson, forward-looking statements include, but are not limited to, statements relating to plans and timing for initiating a Phase 2 clinical study of DARE-HPV, Daré’s expectation of receipt of additional funding under its ARPA-H award to support development, including the planned Phase 2 study, of DARE-HPV, Daré’s ability to advance DARE-HPV efficiently into Phase 2 and generate meaningful clinical data, DARE-HPV’s potential as a safe and effective treatment for clearance of high-risk HPV infection, the potential for DARE-HPV to be the first FDA-approved therapy for high-risk HPV infection, the potential for DARE-HPV to redefine the treatment paradigm in cervical disease prevention, and the potential market opportunity for DARE-HPV, if approved. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Daré’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release and the “What This Means” segment featuring Ms. Johnson, including, without limitation, risks and uncertainties related to: Daré’s ability to raise additional capital when and as needed to execute its business strategy and continue as a going concern; Daré’s ability to achieve the product development and other milestones required for it to receive additional payments under its ARPA-H award; Daré’s ability to develop, obtain FDA or foreign regulatory approval for, and commercialize its product candidates and to do so on communicated timelines; failure or delay in starting, completing or conducting clinical trials of a product candidate and the inherent uncertainty of outcomes of clinical trials; the risks that positive findings in early clinical and/or nonclinical studies of a product candidate may not be predictive of success in subsequent clinical and/or nonclinical studies of that candidate and that interim data or results from a particular clinical study do not necessarily predict the final results for that study; the potential that a drug product candidate in Phase 2 development may never advance into or through a pivotal clinical study or obtain FDA or foreign regulatory approval; the risk that Daré’s product candidates may fail to demonstrate acceptable safety and tolerability or sufficient efficacy in clinical trials; the risk that the FDA, other regulatory authorities, members of the scientific or medical communities or investors may not accept or agree with Daré’s interpretation of or conclusions regarding data from clinical studies of its product candidates; the risk that development of a product candidate requires more clinical or nonclinical studies than Daré anticipates, or that the duration of a study or number of study subjects must be significantly greater than anticipated; Daré’s reliance on third parties in conducting key aspects of its business, including manufacturing clinical study supplies and commercial product, conducting clinical trials and nonclinical studies, and commercializing products, and Daré’s lack of control over those third parties’ performance; difficulties or delays in establishing and sustaining relationships with third-party collaborators; Daré’s ability to retain its licensed rights to develop and commercialize a product or product candidate; Daré’s ability to satisfy the monetary obligations and other requirements in connection with its exclusive, in-license agreements covering the critical patents and related intellectual property related to its products and product candidates; Daré’s ability to adequately protect or enforce its, or its licensor’s, intellectual property rights; disputes or other developments concerning Daré’s intellectual property rights; product liability claims; governmental investigations or actions relating to Daré’s products or product candidates or the business activities of Daré, its commercial collaborators or other third parties on which Daré relies; changes in healthcare, pharmaceutical, consumer protection or privacy laws and regulatory policies; increased scrutiny from regulators; competitive product launches; a product’s ability to gain market acceptance; product liability claims; the effects of macroeconomic conditions, geopolitical events, and major changes and disruptions in U.S. government policies and operations on Daré’s ability to raise additional capital or on Daré’s operations, financial results and condition, and ability to achieve current plans and objectives; Daré’s ability to maintain compliance with Nasdaq’s continued listing requirements and continue to have its common stock listed on The Nasdaq Capital Market; and cybersecurity incidents or similar events that compromise Daré’s technology systems and/or significantly disrupt Daré’s business or those of third parties on which Daré relies. Daré’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Daré’s risks and uncertainties, you are encouraged to review its documents filed with the U.S. Securities and Exchange Commission, including Daré’s recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Daré undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Contacts:
Daré Bioscience Investor Relations
innovations@darebioscience.com
Source: Daré Bioscience, Inc.
FAQ
What did Daré Bioscience announce about the DARE-HPV IND on March 12, 2026 (DARE)?
When does Daré expect to start the Phase 2 trial for DARE-HPV (DARE)?
How does DARE-HPV differ from current management of persistent high-risk HPV (DARE)?
What funding supports DARE-HPV development and does it dilute shareholders (DARE)?
What risks did Daré cite for investors about the DARE-HPV Phase 2 program (DARE)?
